Bausch Health Companies Stock (NYSE:BHC)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$9.78

52W Range

$3.96 - $11.46

50D Avg

$7.55

200D Avg

$7.66

Market Cap

$3.40B

Avg Vol (3M)

$2.14M

Beta

0.77

Div Yield

-

BHC Company Profile


Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

CA

Employees

20,270

IPO Date

Mar 29, 1994

Website

BHC Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Pharmaceutical Products$3.91B--
Branded and Other Generic Products$960.00M--
Device Products$2.00B--
Other Revenues$94.00M--
Over the Counter Products$1.80B--
Product-$8.05B$8.34B
Product and Service, Other-$78.00M$92.00M

Fiscal year ends in Dec 23 | Currency in USD

BHC Financial Summary


Dec 23Dec 22Dec 21
Revenue$8.76B$8.12B$8.43B
Operating Income$963.00M$1.37B$1.21B
Net Income$-592.00M$-212.00M$-937.00M
EBITDA$963.00M$2.58B$2.58B
Basic EPS$-1.62$-0.59$-2.61
Diluted EPS$-1.62$-0.59$-2.61

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 9:17 PM
Q2 24Aug 01, 24 | 11:50 AM
Q1 24May 02, 24 | 12:00 AM

Peer Comparison


TickerCompany
EBSEmergent BioSolutions Inc.
TLRYTilray Brands, Inc.
HLNHaleon plc
LFCRLifecore Biomedical, Inc.
VTRSViatris Inc.
NBIXNeurocrine Biosciences, Inc.
TAKTakeda Pharmaceutical Company Limited
SHPHShuttle Pharmaceuticals Holdings, Inc.
LSDILucy Scientific Discovery Inc.
TEVATeva Pharmaceutical Industries Limited
ZTSZoetis Inc.
CTLTCatalent, Inc.
PETQPetIQ, Inc.